XML 36 R26.htm IDEA: XBRL DOCUMENT
v3.22.1

License and Collaboration Agreements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2022
Summary of Revenues by Collaboration and by Category of Revenue | The following table summarizes revenues by collaboration, category of revenue, and the method of recognition (in thousands):
|  |  | Three Months Ended March 31, |
Revenues recognized: | Over time | Point in time | 2022 |  |  | 2021 |
Gilead access rights related to the Company's research and development pipeline | * |  | $ | 8,316 |  |  | $ | 7,711 |
License and development services for all Gilead programs | * |  |  | 7,939 |  |  |  | - |
Taiho access rights | * |  |  | 1,750 |  |  |  | 1,750 |
Total collaboration and license revenues |  |  | $ | 18,005 |  |  | $ | 9,461 |
Summary of Revenue Recognized as a Result of Changes in Deferred Revenue | The Company recognized the following revenue as a result of changes in the deferred revenue balance during the period below (in thousands):
| Three Months Ended March 31, |
Revenue recognized in the period from: | 2022 |  | 2021 |
Amounts included in deferred revenue at the beginning of the period | $ | 18,005 |  | $ | 9,461 |
Performance obligations satisfied in a previous period |  | - |  |  | - |
Schedule of Payments Allocated to Performance Obligations | The Company determined that the Amended Gilead Collaboration Agreement represented a contract modification under the application of ASC 606. At the amendment closing date, the Company allocated the transaction price to the new and remaining performance obligations identified as follows:
|  |  |  | Amount |
Allocation of transaction price |  |  |  |  |
Deferred revenues as of 12/21/2021 |  |  |  | $ | 165,086 |
Option payment for Domvanalimab |  |  |  |  | 275,000 |
Option payment for Etrumadenant |  |  |  |  | 250,000 |
Option payment for Quemliclustat |  |  |  |  | 200,000 |
Total transaction price allocated to performance obligations |  |  |  | $ | 890,086 |
Allocation to performance obligations |  | Distinct | Combined | Amount |
Domvanalimab license |  | * |  | $ | 328,838 |
Etrumadenant license and R&D activities |  |  | * |  | 218,722 |
Quemliclustat license and R&D activities |  |  | * |  | 175,618 |
Domvanalimab R&D activities |  | * |  |  | 34,528 |
Zimberelimab R&D and commercial services |  | * |  |  | 11,243 |
Access rights related to the Company's research and development pipeline |  | * |  |  | 84,076 |
Material rights to option continuation periods |  | * |  |  | 37,061 |
Total |  |  |  | $ | 890,086 |
Gilead and Taiho |
Summary of Revenues | The following table summarizes the revenues recognized from the Company’s collaboration agreements with Gilead and Taiho Pharmaceutical Co., Ltd. (Taiho) (in thousands):
|  |  | Three Months Ended March 31, |
|  |  | 2022 |  |  | 2021 |
Other collaboration revenue |  |  | $ | 10,066 |  |  | $ | 9,461 |
License and development services revenue |  |  |  | 7,939 |  |  |  | - |
Total collaboration and license revenues |  |  | $ | 18,005 |  |  | $ | 9,461 |

X
- Definition Schedule of payments allocated to performance obligations. + References No definition available. + Details
Name: | rcus_ScheduleOfPaymentsAllocatedToPerformanceObligationsTableTextBlock
Namespace Prefix: | rcus_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of revenues. + References No definition available. + Details
Name: | rcus_SummaryOfRevenuesTableTextBlock
Namespace Prefix: | rcus_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + References Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765 + Details
Name: | us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=rcus_GileadSciencesIncAndTaihoPharmaceuticalCoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |